Arrese D, McNally ME, Chokshi R, Feria-Arias E, Schmidt C, Klemanski D, Gregory G, Khabiri H, Shah M, Bloomston MExtrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.Ann Surg Oncol 20(4) 1114-20 4/1/2013
Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PGComplete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Clin Cancer Res 18(11) 3170-9 6/1/2012
Jones NB, Shah MH, Bloomston MLiver-directed therapies in patients with advanced neuroendocrine tumors.J Natl Compr Canc Netw 10(6) 765-74 6/1/2012
Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, Salem RRadiation pneumonitis following yttrium-90 radioembolization: case report and literature review.J Vasc Interv Radiol 23(5) 669-74 5/1/2012
Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MHA dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Invest New Drugs 30(2) 629-38 4/1/2012
Koh YW, Shah MH, Agarwal K, McCarty SK, Koo BS, Brendel VJ, Wang C, Porter K, Jarjoura D, Saji M, Ringel MDSorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.Endocr Relat Cancer 19(1) 29-38 2/1/2012
Caronia LM, Phay JE, Shah MHRole of BRAF in thyroid oncogenesis.Clin Cancer Res 17(24) 7511-7 12/15/2011
Liebner DA, Shah MHThyroid cancer: pathogenesis and targeted therapy.Ther Adv Endocrinol Metab 2(5) 173-95 10/1/2011